The American Society of Clinical Oncology meeting this year had close to 6,000 abstracts submitted for review, with 4,882 abstracts published in conjunction with this conference. Of these abstracts 2,392 were presented onsite during the poster discussion, oral abstract, and poster sessions.

Memorial Sloan Kettering contributed 296 abstracts which represents an increase of approximately 15% from last year’s total abstract count. Also last year, there were 7 MSK authors that published 10 or more abstracts. This year there were 12 MSK authors that published 10 or more abstracts: C.A. Hudis (18), M.F. Berger (15), D.M. Hyman (15), M.G. Kris (15), R.J. Motzer (13), M.E. Arcila (12), L.B. Saltz (11), M. Ladanyi (10), H.I. Scher (10), D.B. Solit (10), M.H. Voss (10), and J.D. Wolchok (10).

The top three categories (as determined by ASCO) were Genitourinary (Nonprostate) Cancer (26), Gastrointestinal (Noncolorectal) Cancer (21), and Lung Cancer-Non-Small Cell Metastatic (21). The abstracts include three on the historic IBM Watson Oncology application being implemented at MSK.


17. Atkinson TM, Satele DV, Sloan JA, Mehedint D, Lafky JM, Basch EM, Dueck AC. Comparison between clinician- and patient-reporting of baseline (BL) and post-BL symptomatic toxicities in cancer cooperative group clinical trials (NCCTG N0591 [alliance]). ASCO Meeting Abstracts. 2015 May 18; 33(15_suppl): 9520. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9520


analysis of patient reported outcomes (PRO) on chemotherapy randomization. 

**ASCO Meeting Abstracts.** 2015 May 18; 33(15_suppl): 5525.  
http://meeting.asco.org/cgi/content/abstract/33/15_suppl/5525


**ASCO Meeting Abstracts.** 2015 May 18; 33(15_suppl): 3565.  
http://meeting.asco.org/cgi/content/abstract/33/15_suppl/3565


**ASCO Meeting Abstracts.** 2015 May 18; 33(15_suppl): TPS3093.  
http://meeting.asco.org/cgi/content/abstract/33/15_suppl/TPS3093


**ASCO Meeting Abstracts.** 2015 May 18; 33(15_suppl): e17775.  
http://meeting.asco.org/cgi/content/abstract/33/15_suppl/e17775


http://meeting.asco.org/cgi/content/abstract/33/15_suppl/9587


**ASCO Meeting Abstracts.** 2015 May 18; 33(15_suppl): 5036.  
http://meeting.asco.org/cgi/content/abstract/33/15_suppl/5036


**ASCO Meeting Abstracts.** 2015 May 18; 33(15_suppl): 5507.  
http://meeting.asco.org/cgi/content/abstract/33/15_suppl/5507


**ASCO Meeting Abstracts.** 2015 May 18; 33(15_suppl): TPS4571.  
http://meeting.asco.org/cgi/content/abstract/33/15_suppl/TPS4571


**ASCO Meeting Abstracts.** 2015 May 18; 33(15_suppl): 8537.  
http://meeting.asco.org/cgi/content/abstract/33/15_suppl/8537


**ASCO Meeting Abstracts.** 2015 May 18; 33(15_suppl): 6548.  
http://meeting.asco.org/cgi/content/abstract/33/15_suppl/6548


39. Cercek A, Park V, Yaeger RD, Reidy DL, Kemeny NE, Stadler ZK, Segal NH, Varghese AM, Saltz L. Oxaliplatin can be safely infused at a rate of 1mg/m2/min. *ASCO Meeting Abstracts*. 2015 May 18; 33(15_suppl): e14665. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e14665


http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8538

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4577

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8550

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/107

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11000

49. Connell LC, Harding JJ, Lowery MA, Kemeny NE, Cercek A, Abdelgawad MI, O'Reilly EM, Saltz L, Abou-Alfa GK. Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC). *ASCO Meeting Abstracts.* 2015 May 18; 33(15_suppl): e15146.  
http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15146

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e12506

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e18030

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4000

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e16040


61. Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze S, Staddon AP, Milhem MM, Elias AD, Ganjoo KN, Tawbi HA, Van Tine BA, Spira AI, Dean AP, Khokhar NZ, Park CY, Knoblauch RE, Parekh TV, Maki RG, Patel S. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). ASCO Meeting Abstracts. 2015 May 18; 33(15_suppl): 10503. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10503


84. Flynn KE, Jeffery DD, Andersen BL, Siston AK, Jhingran A, Baron SR, Reese JB, Coady DJ, Carter J, Barbera LC. Self-reported sexual function measures administered to female cancer patients: A


113. Hobday TJ, Yin J, Pettinger A, Strosberg JR, Reidy DL, Chen HX, Erlichman C. Multicenter prospective phase II trial of bevacizumab (bev) for progressive pancreatic neuroendocrine tumor


142. Lacouture ME, Keefe DMK, Sonis ST, Giri N, Wang T, Reisman A, Sbar E, Gernhardt DR, Jatoi A. Prophylactic doxycycline (doxy) lessens rash from dacomitinib (D) an EGFR inhibitor with no rash or
diarrhea improvement from corticosteroids or probiotics. *ASCO Meeting Abstracts.* 2015 May 18; 33(15_suppl): e19049. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e19049


150. Leidner RS, Patel SP, Fury MG, Ferris RL, McDevitt JT, Lanasa MC, Glisson BS. A phase I study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary clinical activity of MEDI0562 in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). *ASCO Meeting Abstracts.* 2015 May 18; 33(15_suppl): TPS6083. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS6083


152. Liang L, Perez AR, Cangemi NA, Zhou Q, Iasonos A, Alektiar KM, Abu-Rustum N, Makker V. Outcomes of stage IA polyp-limited vs endometrium-limited epithelial high grade endometrial

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8614


http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2072


http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/6507


http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7040

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/511

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5014


http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/605

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5572

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS1112

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2057

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4114

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4146

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS3099


http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2509


extreme responses to pazopanib (PZP) salvage therapy. ASCO Meeting Abstracts. 2015 May 18; 33(15_suppl): e15514. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15514


219. Raut CP, Esrat NJ, Maki RG, Araujo DM, Keir CH, Williams TF, DeMatteo RP. Adjuvant imatinib (IM) for patients (pts) with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence: PERSIST-5 planned 3-year interim analysis. ASCO Meeting Abstracts. 2015 May 18; 33(15_suppl): 10537. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10537


http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15183

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e15176

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3003

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1051

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8064

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8032

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8026

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9050

patients with advanced myeloid malignancies. ASCO Meeting Abstracts. 2015 May 18; 33(15_suppl): e18025. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e18025

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/604

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e16106

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e22185

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3010

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5063

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8515

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10072

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5000

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7055


251. Shoushtari AN, Postow MA, Horvat TZ, Adel NG, Dang T, Chapman PB. Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events. ASCO Meeting Abstracts. 2015 May 18; 33(15_suppl): e20023. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e20023


259. Spigel DR, Reckamp KL, Rizvi NA, Poddubskaya E, West HJ, Eberhardt WEE, Baas P, Antonia SJ, Pluzanski A, Vokes EE, Holgado E, Waterhouse DM, Ready N, Gainor JF, Aren OR, Horn L, Paz-Ares L, Baudelet C, Lestini BJ, Brahmer JR. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-
programmed death-1 (PD-1) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). *ASCO Meeting Abstracts.* 2015 May 18; 33(15_suppl): 8009. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8009


http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2503

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/7051

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/1003

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS1108

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4110

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/10012

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/4522

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4579

http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS4583


